Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Javenlin hires former FDA director

Executive Summary

Former FDA Anesthetics, Analgesics & Drug Abuse Division Deputy Director Curtis Wright becomes VP of risk management and regulatory affairs at Javenlin effective immediately. In the newly created post, Wright will oversee health risk assessments, with a focus on abuse associated with pain products, which the company characterized as a growing regulatory concern. Wright will provide risk management oversight for Javenlin's three pain candidates in Phase II development. He joins Javenlin following his June departure from Purdue Pharma, where he worked as exec medical director of clinical risk assessment. Javenlin Pharmaceuticals was known as Intrac prior to Sept. 7...

You may also be interested in...



US FDA Cast As Culpable Player In Opioid Epidemic In Hulu’s Dopesick Series

Show depicts former agency officials approving OxyContin labeling that enabled Purdue to market it as nonaddictive and subsequently refusing pleas to restrict its use.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel